Document Detail

Bacteraemia in Malawian neonates and young infants 2002-2007: a retrospective audit.
Jump to Full Text
MedLine Citation:
PMID:  22587884     Owner:  NLM     Status:  In-Data-Review    
OBJECTIVES: To assess the causes of bacteraemia in young infants and susceptibility to first-line antibiotics (benzylpenicillin plus gentamicin) at the Queen Elizabeth Central Hospital (QECH), Malawi during 2002-2007.
DESIGN: Retrospective analysis of demographic and microbiological data using laboratory records.
SETTING: QECH is Malawi's largest hospital with 7000 neonates admitted annually, 9% for septicaemia.
PATIENTS: All infants aged 60 days or less admitted to QECH that had a blood culture taken over the 6-year period.
MAIN OUTCOME MEASURES: 6754 blood cultures were taken. 3323 organisms were isolated: one-third were pathogens, two-thirds contaminants. Gram-positive organisms (53%) were more common than gram-negatives (47%). Four organisms made up half of all pathogens: Staphylococcus aureus (15.3%), group B streptococci (13.5%), non-typhoidal salmonellae (12.6%) and Escherichia coli (10.5%). Apart from non-typhoidal salmonellae and Streptococcus pneumoniae, most organisms were more common in the first week of life than later. Overall, 28% of isolates during 2002-2007 were resistant to first-line antibiotic, higher than observed during 1996-2001 (22%). Penicillin susceptibility fluctuated while gram-negative resistance to gentamicin increased from 17% to 27% over the study period.
CONCLUSIONS: In the QECH, pathogens causing young infant sepsis are an unusual mix of organisms seen in both developed and developing countries. Resistance to first-line antibiotics is higher than observed in most studies. Ongoing monitoring is needed and clinical outcome data would aid interpretation of findings. A high proportion of blood cultures were contaminated with skin flora-improved training and supervision of phlebotomists are needed to improve the utility of taking blood cultures.
Amanda Gwee; Benjamin Coghlan; Dean Everett; Newton Chagoma; Amos Phiri; Lorna Wilson; Elizabeth Molyneux
Related Documents :
3886004 - Cimetidine in labour: absence of adverse effect on the high-risk fetus.
22591124 - Implementation and results of bedside hearing screening with automated auditory brainst...
11811284 - Effect of insulin and insulin-like growth factor i on fetal macrosomia in healthy women.
2413064 - Elevated beta-human chorionic gonadotropin and testosterone in cord serum of male infan...
11755034 - Oligosaccharides: application in infant food.
12964694 - Adolescent pregnancy.
Publication Detail:
Type:  Journal Article     Date:  2012-05-15
Journal Detail:
Title:  BMJ open     Volume:  2     ISSN:  2044-6055     ISO Abbreviation:  BMJ Open     Publication Date:  2012  
Date Detail:
Created Date:  2012-05-16     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101552874     Medline TA:  BMJ Open     Country:  England    
Other Details:
Languages:  eng     Pagination:  -     Citation Subset:  -    
Department of General Medicine, The Royal Children's Hospital, Melbourne, Australia.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Full Text
Journal Information
Journal ID (nlm-ta): BMJ Open
Journal ID (iso-abbrev): BMJ Open
Journal ID (publisher-id): bmjopen
Journal ID (hwp): bmjopen
ISSN: 2044-6055
Publisher: BMJ Group, BMA House, Tavistock Square, London, WC1H 9JR
Article Information
Download PDF
© 2012, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to
Received Day: 24 Month: 1 Year: 2012
Accepted Day: 28 Month: 3 Year: 2012
collection publication date: Year: 2012
Electronic publication date: Day: 15 Month: 5 Year: 2012
pmc-release publication date: Day: 15 Month: 5 Year: 2012
Volume: 2 Issue: 3
E-location ID: e000906
ID: 3358614
PubMed Id: 22587884
Publisher Id: bmjopen-2012-000906
DOI: 10.1136/bmjopen-2012-000906

Bacteraemia in Malawian neonates and young infants 2002–2007: a retrospective audit Alternate Title:Bacteraemia in Malawian infants 2002–2007
Amanda Gwee1
Benjamin Coghlan2
Dean Everett34
Newton Chagoma3
Amos Phiri5
Lorna Wilson5
Elizabeth Molyneux6
1Department of General Medicine, The Royal Children's Hospital, Melbourne, Australia
2Centre for International Health, Burnet Institute, Melbourne, Australia
3Malawi-Liverpool-Wellcome Trust Clinical Research Programme, Blantyre, Malawi
4Department of Clinical Infection, Microbiology and Immunology, Institute of Infection & Global Health, University of Liverpool, UK
5Laboratory, Queen Elizabeth Central Hospital, Blantyre, Malawi
6Department of Paediatrics, College of Medicine, Blantyre, Malawi
Correspondence: Correspondence to Dr Amanda Gwee;


The Queen Elizabeth Central Hospital (QECH) in Blantyre, Malawi, is the country's largest hospital and a referral centre for the southern region. Seven thousand neonates are admitted annually, including ∼9% for septicaemia. Septic infants aged 60 days or less are treated with parenteral penicillin (50 000 units or 30 mg/kg three or four times daily) and gentamicin (6 mg/kg/day) as per hospital policy. Earlier studies (1996–2001) at the QECH had shown some resistance to this antibiotic regimen.1, 2 We reviewed microbiological data from blood cultures taken from children in this age group during a 6-year period, 2002 to 2007, to assess further changes in the causes of bacterial infections and antibiotic resistance.


We conducted a retrospective analysis of all blood cultures from children aged 60 days or less admitted to QECH during 2002–2007. We collected demographic and microbiological data from ward admission and laboratory registers and validated these against the electronic microbiology database. Case notes were not linked to these registers, so comorbid conditions (eg, malnutrition, HIV status, low birth weight), length of hospital stay and clinical outcomes could not be assessed. Data on bacterial colonisation of mothers from vaginal swabs and antibiotic treatment during delivery were not available.

Prior to 2006, routine blood cultures were collected on clinical suspicion of septicaemia after malaria had been excluded. In order to save resources, from 2006, they were taken only if first-line antibiotic therapy had failed.

Samples were processed in the Malawi-Liverpool-Wellcome Trust Clinical Research Programme at QECH using British Society for Antimicrobial Chemotherapy guidelines to identify organisms and test for resistance to antibiotics.3 Isolates were classified as being either resistant or susceptible to an antibiotic using the disc diffusion method—minimum inhibitory concentrations were not routinely quantified.

Mixed skin flora and four specific organisms were considered contaminants and as such were excluded from the analysis: Bacillus sp, Coagulase-negative staphylococcus, diphtheroids and Micrococcus sp. Although Coagulase-negative staphylococcus are recognised pathogens in intensive care settings, particularly for premature and low birth weight infants, we classified them as contaminants because care of sick infants at the QECH does not involve central venous access or other invasive care procedures.

EpiData 3.1 (EpiData Association) was used for data entry. Data were analysed by isolates, age group, year and resistance to antibiotics using Stata V.10.0 (StataCorp LP). Missing data are reported to aid interpretation of findings. In selected instances, we compared our data with findings from an earlier audit of blood (and cerebrospinal fluid) cultures in the QECH.2

Ethical approval was not required for a retrospective audit of unlinked laboratory data.

Organisms isolated

Over the 6-year period, 6754 blood cultures were performed on infants aged 60 days or less. Fifty-five per cent (3726) were collected from inpatients of the main paediatric nursery that were mostly born outside the hospital; 40% (2673) were from infants in the special care baby unit that were born at the QECH or in another healthcare facility and transferred directly to this unit. Two hundred and sixty-three specimens were from children in other wards (3.9%) or the ward was not recorded (1.4%). The number of blood cultures collected increased annually until 2005, after which blood cultures were taken only in children who did not clinically improve on first-line therapy.

Forty-four per cent (2971) of blood cultures grew a single organism and 2.5% (168) grew two or more organisms (table 1). One-third (31%) of organisms were defined as clinically important pathogens, while two-thirds (69%) were contaminants. The proportion of contaminants was similar in different age groups. The proportion of blood cultures with contaminants, pathogens and no growth were similar to those from an earlier audit (table 2).2

All pathogens were bacterial with the exception of a single yeast isolate (Candida sp) cultured in 2005. A greater proportion of gram-positive bacteria (53%; 551 isolates) were isolated than gram-negative bacteria (47%; 493 isolates). The change in policy in 2006 to collect blood cultures only from children who failed empiric first-line treatment led to a number of changes: there was a reduction in the proportion of pathogens grown—11.4% of all cultures had at least one pathogen in 2006–2007 compared with 15.7% in 2002–2005 (OR=0.7, 95% CI 0.7 to 0.8, p=0.000); and gram-negative organisms became more common in 2006–2007 compared with 2002–2005 (OR=1.6, 95% CI 1.2 to 2.2, p=0.003). The 10 most common organisms isolated constituted 85% of all cultured pathogens (table 3). Four organisms made up over half of all pathogens isolated: Staphylococcus aureus (15.3%), group B streptococci (GBS) (13.5%), non-typhoidal salmonellae species (NTS) (12.6%) and Escherichia coli (10.5%). These four organisms were the four most common isolates for 3 of the 6 years under review and made up a significant proportion of isolates in each age group: 0–7 days (47%), 8–28 days (66%) and 29–60 days (51%). With the exception of NTS and Streptococcus pneumoniae, most organisms were more common in the first week of life than later (figures 1 and 2).

Antibiotic susceptibility

More than 25% of tested isolates was resistant to both penicillin and gentamicin in 2003, 2005, 2006 and 2007, with 28% resistant for the combined 6-year period. Organisms were more likely to be resistant to first-line therapy in 2007 than 2002 (OR=2.2, 95% CI 1.1 to 4.3, p=0.024); however, there was no difference for the period 2002–2005 when cultures were collected routinely for septicaemia compared with 2006–2007 when cultures were collected after first-line treatment had failed (OR=1.0, 95% CI 0.7 to 1.5, p=0.86). For common organisms (NTS, E coli, Klebsiella sp, S aureus), the proportion susceptible to first-line antibiotics in 2006–2007 was similar to or greater than in 2002–2005.

Susceptibility to penicillin fluctuated annually for all isolates, while the resistance of gram-negative organisms to gentamicin—the main antibiotic used to treat gram-negative sepsis—increased from 17% in 2002 to almost 27% in 2007 (OR=1.8, 95% CI 0.8 to 4.2, p=0.18) (tables 4 and 5). A small number of both gram-negative and gram-positive bacteria were resistant to ceftriaxone, the second-line antibiotic therapy (including a single S pneumoniae isolate that showed borderline intermediate resistance to ceftriaxone (zone=26 mm, sensitive=27 mm, resistant=22 mm)). Most gram-negative isolates were susceptible to ciprofloxacin throughout the study period (tables 4 and 5), whereas gram-negative resistance to chloramphenicol, tetracycline and co-trimoxazole remained consistently high for all common organisms (table 5). The high proportion of gram-positive organisms resistant to penicillin (47% for 2002–2007) (table 4) reflects the frequency of S aureus infections, of which 94% of isolates were penicillin resistant. Of the staphylococci tested (32% of total), only 2% were resistant to cloxacillin.

Isolated organisms

In our study, a clinically important bacterial pathogen was isolated from 15% (992) of young infant blood specimens. The proportion of pathogens that were gram positive (53%) and gram negative (47%) was similar to the previous audit from 1996 to 2001 in the same hospital.2 Our observations among this cohort differ from those reported elsewhere in Africa, which describe a preponderance of gram-negative bacteria.4 The range of organisms found in our study fits somewhere between those classically observed in developed countries—such as GBS and S aureus5—and those more commonly reported from developing countries including Klebsiella, Acinetobacter and Pseudomonas.6 The four most common pathogens were S aureus, GBS, NTS and E coli. Similar findings from earlier studies in the French Antilles7 and South Africa,8 particularly with regard to the frequency of GBS, led some researchers to speculate about an epidemiological transition occurring in middle-income countries of bacteria infecting neonates or an inherent bias in reporting with many neonates born at home dying before reaching hospital.6 Both suppositions seem unlikely for the QECH: the United Nations ranks Malawi in the lowest category for development, and the type of organisms we isolated have remained unchanged since 1996,2 while most (79%) mothers deliver in health facilities in this part of Malawi.9 The complex local microbial ecology may partly explain the range of organisms seen in the QECH.

Undernourished children (10% of paediatric inpatients in the QECH) are more likely than well-nourished children to have bacteraemia on admission and to be infected with gram-negative organisms.10 Gram-negative sepsis due to NTS, is associated with the wet (malaria) season in both The Gambia11 and Malawi12 and may explain the predominance of NTS in our study compared with reports from other developing countries where Klebsiella spp and E coli are more common.4 NTS infection has also been shown to be common among adults with HIV in Malawi with a high recurrence rate after treatment.13

Recent data from Zimbabwe found no difference in GBS colonisation rates between women with and without HIV-1 infection.14, 15 Studies within Malawi demonstrated that GBS with type 3-polysaccharide antigen was common and more virulent than other serotypes.16 In contrast, in the Gambia, maternal colonisation with GBS type 3 is infrequent (6%) and neonatal GBS sepsis is uncommon.17

S pneumoniae was a leading cause of sepsis in older infants aged 28–60 days, a finding consistent with other local and international studies.18

The pattern of pathogens reflects the fact that neonates admitted to our wards are from both home and health facility deliveries. The 2004 national demographic and health survey showed that of all deliveries in the southern region of Malawi, the catchment area for the QECH, 79% were in health facilities.9 We were not able to track the place or time of birth in relation to the time of hospital admission in our study. Therefore, we cannot separate community-acquired infections from those acquired in health facilities or maternally spread organisms from those transmitted by unhygienic practices in health facilities or at home. Nonetheless, the prevalence of gram-negative and S aureus infections in young infants of all ages suggests that hospital-acquired infections are important, and the high proportion of contaminants isolated likely reflects a general lack of infection control practices in the hospital and the need for improved training.

The 2006 policy to take blood cultures only when first-line therapy failed led to relatively fewer pathogens cultured overall. This is likely a function of selecting children whose symptoms were due to fastidious organisms and non-bacterial causes as well as those whose clinical improvement lagged behind their microbiological improvement (ie, they still had symptoms but no bacteraemia). The policy change also led to more gram-negative isolates that may reflect a reduced susceptibility of these organisms to first-line antibiotics as was seen in 2007 compared with 2002.

Antibiotic resistance and implications for empirical first-line antibiotic regimens

In this study, almost three in 10 isolates were resistant to first-line antimicrobial therapy. This is slightly higher than was recorded in the previous audit and higher than has been observed in much of the literature.2 It is also important to note the worrying shift towards resistance to ceftriaxone, which had not been present earlier and has emerged with the increasing use of ceftriaxone as second-line therapy. Streptococcal species resistance is of particular concern as there is no locally available third-line antibiotic therapy.

As in other developing countries, we found the appearance of multidrug-resistant gram-negative organisms in particular Klebsiellae.4 Resistance of E coli to gentamicin rose from 7% during 1996–2001 to 20% during 2002–2007. Unfortunately, we lacked clinical data to compare in vitro and in vivo resistance for these pathogens, which differed in past assessments in the QECH.2

During the 6-year period of our study, there was a 10% increase in resistance to chloramphenicol for gram-positive pathogens possibly reflecting the widespread use of this agent for first-line treatment of sepsis, especially in malnourished children. Few isolates of S aureus were resistant to cloxacillin, a pattern seen elsewhere in the developing world,10 and most remain susceptible to gentamicin.

Although this is a large data set and the level of resistance to first-line treatment of isolated pathogens is high and rightly warrants concern, the implications for antibiotic therapy are not straightforward. On the one hand, 28% of pathogens were resistant to first-line antibiotics. Some laboratory-based surveillance systems recommend revising treatment when more than 5% of isolates have in vitro resistance to a particular antibiotic.19 On the other hand, of all blood culture specimens taken just one in 25 grew a resistant organism. Interestingly, there was no difference in the level of resistance to first-line therapy before and after the 2006 change in policy for the indication of taking blood cultures.


The pathogens isolated may not reflect the causative organisms for young infant sepsis in rural Malawi for a number of reasons: deaths of newborns outside the hospital were not captured,20 the number of isolates with unknown ages could have affected the distribution of organisms across the age categories, the high number of contaminants isolated may have obscured the detection of more fastidious pathogens and isolates taken after the change in policy for taking blood cultures may reflect organisms that grow despite antibiotic exposure. The policy change may also have affected sensitivity patterns when compared with previous studies. Length of stay, which has been associated with nosocomial spread of pathogens with higher levels of antibiotic resistance, was not recorded in our data set.


This study is one of the largest single-site studies of its kind in developing countries and highlights the importance of local aetiological assessments of young infant sepsis for review of empiric treatment. Arguably, such assessments are becoming more important as standard treatment recommendations from international bodies are increasingly applied. Audits should ideally be correlated with clinical outcomes and separate community-acquired from hospital-acquired infections to determine the most appropriate first-line antibiotic regimens. This would also facilitate consideration of other preventive measures such as vaccination and screening. For example, the high prevalence of GBS sepsis in Malawi (combined with a high case death rate (33%)) warrants routine screening of mothers with antibiotic prophylaxis and maternal immunisation.16 The high proportion of blood cultures contaminated by skin flora in both this and the previous audit shows an urgent need for additional training and supervision. Other studies of children have recorded lower contaminant rates of 13%–23%.21, 22 Trained phlebotomists and a formal internal system of monitoring and quality assurance should be considered.23


To cite: Gwee A, Coghlan B, Everett D, et al. Bacteraemia in Malawian neonates and young infants 2002–2007: a retrospective audit. BMJ Open 2012;2:e000906. doi:10.1136/bmjopen-2012-000906

Contributors: AG and BC carried out the data entry, data analysis, literature review and write up. AP and LW assisted with microbiological analysis and interpretation of data. DE and NC were responsible for cross checking the entered data with the Wellcome Trust Database. EM was responsible for the study design, overall supervision of the project and interpretation of data. All authors were involved in editing the manuscript and reviewing the final version prior to publication.

Funding:This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests: None.

Provenance and peer review: Not commissioned; externally peer reviewed.

Data sharing statement: The complete dataset is available from the corresponding author at pending approval from the Malawi-Liverpool-Wellcome Trust and senior staff at the Queen Elizabeth Central Hospital, Blantyre. Consent was not obtained from parents or carers of infants, but the presented data are anonymised and risk of identification is low.

We thank Professor Rob Heyderman for reviewing the article and for providing access to the electronic microbiology database to ensure data were as complete as possible. We also thank Amanda Walsh for her review of the manuscript. We thank the nursing staff and doctors who work at the Queen Elizabeth Central Hospital who strive to provide quality care in a resource-limited setting.

1. Walsh AL,Phiri AJ,Graham SM,et al. Bacteremia in febrile Malawian children: clinical and microbiologic features. Pediatr Infect Dis JYear: 2000;19:312–1810783021
2. Milledge J,Calis JC,Graham SM,et al. Aetiology of neonatal sepsis in Blantyre, Malawi: 1996-2001. Ann Trop PaediatrYear: 2005;25:101–1015949198
3. Andrews JM. ; BSAC standardized disc susceptibility testingBSAC standardized disc susceptibility testing method (version 6). J Antimicrob ChemotherYear: 2007;60:20–4117460026
4. Zaidi AK,Huskins WC,Thaver D,et al. Hospital-acquired neonatal infections in developing countries. LancetYear: 2005;365:1175–8815794973
5. Bizzarro MJ,Raskind C,Baltimore RS,et al. Seventy-five years of neonatal sepsis at Yale: 1928-2003. PediatricsYear: 2005;116:595–60216140698
6. Vergnano S,Sharland M,Kazembe P,et al. Neonatal sepsis: an international perspective. Arch Dis Child Fetal Neonatal EdYear: 2005;90:F220–4 [Review].15846011
7. Robillard PY,Nabeth P,Hulsey TC,et al. Neonatal bacterial septicemia in a tropical area. Four-year experience in Guadeloupe (French West Indies). Acta PaediatrYear: 1993;82:687–98374220
8. Bomela HN,Ballot DE,Cooper PA. Is prophylaxis of early-onset group B streptococal disease appropriate for South Africa?S Afr Med JYear: 2001;91:858–6011732458
9. National Statistical Office, Malawi and ORC MacroMalawi Demographic and Health Survey 2004. Calverton, MarylandYear: 2005 (accessed Jun 2010).
10. Reed RP,Wegerhoff FO,Rothberg AD. Bacteraemia in malnourished rural African children. Ann Trop PaediatrYear: 1996;16:61–88787368
11. O'Dempsey TJ,McArdle TF,Lloyd-Evans N,et al. Importance of enteric bacteria as a cause of pneumonia, meningitis and septicemia among children in a rural community in The Gambia, West Africa. Pediatr Infect Dis JYear: 1994;13:122–88190537
12. Graham SM,Walsh AL,Molyneux EM,et al. Clinical presentation of non-typhoidal Salmonella bacteraemia in Malawian children. Trans R Soc Trop Med HygYear: 2000;94:310–1410975008
13. Gordon MA,Banda HT,Gondwe M,et al. Non-typhoidal salmonella (NTS) bacteraemia in Malawian adults: a severe, recrudescent, HIV-associated illness. Malawi Med JYear: 2003;15:47–51
14. Mavenyengwa RT,Moyo SR,Nordbo SA. Streptococcus agalactiae colonization and correlation with HIV-1 and HBV seroprevalence in pregnant women from Zimbabwe. Eur J Obstet Gynecol Reprod BiolYear: 2010;150:34–820189288
15. El Beitune P,Duarte G,Maffei CM,et al. Group B Streptococcus carriers among HIV-1 infected pregnant women: prevalence and risk factors. Eur J Obstet Gynecol Reprod BiolYear: 2006;128:54–816621230
16. Gray KJ,Bennett SL,French N,et al. Invasive group B Streptococcal infection in infants, Malawi. Emerg Infect DisYear: 2007;13:223–917479883
17. Suara RO,Adegbola RA,Mulholland EK,et al. Seroprevalence of antibodies to group B Streptococcal polysaccharides in Gambian mothers and their newborns. J Natl Med AssocYear: 1998;90:109–149510625
18. Lehmann D,Michael A,Omena M,et al. Bacterial and viral etiology of severe infection in children less than three months old in the highlands of Papua New Guinea. Pediatr Infect Dis JYear: 1999;18(Suppl 10):S42–910530573
19. Australian Government, Department of Health and AgeingAustralian Gonococcal Surveillance Programme. Year: 2011 (accessed 20 Dec 2011).
20. Darmstadt GL,Batra M,Zaidi AK. Oral antibiotics in the management of serious neonatal bacterial infections in developing country communities. Pediatr Infect Dis JYear: 2009;28(Suppl 1):S31–619106761
21. Sigauque B,Roca A,Mandomando I,et al. Community-acquired bacteremia among children admitted to a rural hospital in Mozambique. Pediatr Infect Dis JYear: 2009;28:108–1319131902
22. Talbert AW,Mwaniki M,Mwarumba S,et al. Invasive bacterial infections in neonates and young infants born outside hospital admitted to a rural hospital in Kenya. Pediatr Infect Dis JYear: 2010;29:945–920418799
23. Kaye KS,Engemann JJ,Fulmer EM,et al. Favorable impact of an infection control network on nosocomial infection rates in community hospitals. Infect Control Hosp EpidemiolYear: 2006;27:228–3216532408


[Figure ID: fig1]
Figure 1 

Most frequent pathogenic gram-positive isolates by age group (n=500; excludes 51 isolates where age was not reported).

[Figure ID: fig2]
Figure 2 

Most frequent pathogenic gram-negative isolates by age group (n=427; excludes 66 isolates where age was not reported). *Category is a combination of related organisms: Acinetobacter sp: A baumannii, A lwoffii and other Acinetobacter sp. Enterobacter sp: E agglomerans, E cloacae, E sakazakii and other Enterobacter sp. Klebsiella sp: K pneumoniae, K oxytoca and other Klebsiella sp. NTS species (non-typhoidal salmonellae): S typhimurium, S enteritidis and other Salmonella sp.

[TableWrap ID: tbl1] Table 1 

Summary of blood culture specimens and isolates, 2002–2007

Isolates Number of isolates per specimen Number of blood cultures
Total number of isolates
2002 2003 2004 2005 2006 2007 Total Pathogens Contaminants All
None 0 409 576 676 1002 525 427 3615
Pathogens 1 150 186 153 205 97 71 862 862 862
2 2 15 18 3 2 40 80 80
3 3 3 9 9
Contaminants 1 270 458 379 540 274 188 2109 2109 2109
2 20 12 3 3 38 76 76
Mixed growth (contaminant: pathogen) 1:1 31 33 6 3 73 73 73 146
1:2 5 1 1 7 14 7 21
2:1 1 5 6 6 12 18
0:1* 1 1 1 2
Total 829 1222 1283 1817 909 694 6754 1045 2277 3323

*Two organisms were grown—one was confirmed as a pathogen; however, the details of the other organism were not recorded.

[TableWrap ID: tbl2] Table 2 

Comparison of neonatal blood culture audits: 1996–2001 versus 2002–2007

Year of audit Blood cultures Proportion* of blood cultures with
Proportion of gram-positive: gram-negative pathogens
No growth Contaminants Pathogen(s)
1996–2001 2442 50% (1213) 32% (781) 18% (448) 54%: 46%
2002–2005* 5151 50% (2663) 34% (1755) 16% (809) 55%: 45%
2006–2007* 1603 60% (952) 30% (478) 11% (183) 43%: 57%
2002–2007* 6754 54% (3615) 33% (2233) 15% (992) 53%: 47%

*Cumulative proportions may exceed 100% during 2002–2007 as some cultures grew both pathogens and contaminants.

[TableWrap ID: tbl3] Table 3 

Ten most common pathogenic bacterial isolates for all age groups, 2002–2007 (includes isolates of those infants whose age was unknown)

Bacterial isolates Proportion of pathogens in each year
2002 (n=150) 2003 (n=190) 2004 (n=234) 2005 (n=281) 2006 (n=111) 2007 (n=78) 2002–2007 (n=1044)
Gram positive
Staphylococcus aureus 19% 19% 15% 16% 13% 4% 15.3%
Streptococcus—group B (S agalactiae) 15% 13% 11% 18% 13% 6% 13.5%
Streptococcus—alpha haemolytic 3% 2% 11% 12% 5% 5% 7.4%
Streptococcus pneumoniae 5% 4% 6% 5% 6% 15% 5.9%
Streptococcus—group D (Enterococcus) 1% 2% 4% 10% 3% 4% 4.4%
 Other gram positive 7% 5% 9% 4% 10% 0% 6.3%
Gram negative
Non-typhoidal Salmonellae sp* 23% 14% 9% 7% 16% 18% 12.6%
Escherichia coli 7% 13% 12% 7% 10% 19% 10.5%
Klebsiella sp* 6% 9% 4% 6% 10% 14% 7.3%
Enterobacter sp* 2% 5% 5% 5% 5% 4% 4.6%
Acinetobacter sp* 3% 2% 2% 5% 2% 5% 3.1%
 Other gram negative 10% 12% 12% 6% 8% 5% 9.0%

Values in bold represent top three most common organisms in each year.

*Category is a combination of related organisms: Acinetobacter sp: A baumannii, A lwoffii and other Acinetobacter sp. Enterobacter sp: E agglomerans, E cloacae, E sakazakii and other Enterobacter sp. Klebsiella sp: K pneumonia, K oxytoca and other Klebsiella sp. Non-typhoidal Salmonellae sp: S typhimurium, S enteritidis and other Salmonella sp.

[TableWrap ID: tbl4] Table 4 

Antibiotic susceptibility of gram-positive bacteria, 2002–2007 (n=551)

Antibiotic Proportion of isolates susceptible (number tested)
2002 2003 2004 2005 2006 2007 2002–2007
Penicillin 57% (74) 42% (85) 55% (106) 55% (149) 47% (51) 62% (26) 53% (491)
Erythromycin 86% (74) 81% (86) 69% (108) 67% (163) 81% (52) 78% (27) 75% (510)
Chloramphenicol 84% (74) 84% (86) 77% (109) 73% (167) 77% (53) 74% (27) 78% (516)
Co-trimoxazole 40% (75) 45% (84) 46% (105) 47% (165) 40% (53) 22% (27) 43% (509)
Gentamicin 55% (49) 100% (16) 77% (35) 73% (49) 93% (14) 100% (3) 73% (166)
Ceftriaxone 94% (18) 91% (74) 93% (69) 94% (109) 97% (36) 87% (23) 93% (329)
Tetracycline 40% (75) 47% (86) 31% (110) 35% (165) 38% (53) 52% (27) 38% (516)
First-line therapy (penicillin and gentamicin) 88% (75) 60% (86) 78% (107) 74% (155) 71% (51) 73% (26) 74% (500)

[TableWrap ID: tbl5] Table 5 

Antibiotic susceptibility of gram-negative bacteria, 2002–2007 (n=493)

Antibiotic Proportion of isolates susceptible (number tested)
2002 2003 2004 2005 2006 2007 2002–2007
Ampicillin 8% (73) 7% (100) 16% (100) 23% (96) 20% (56) 16% (49) 15% (474)
Chloramphenicol 35% (71) 28% (99) 40% (99) 39% (97) 51% (55) 41% (49) 38% (470)
Co-trimoxazole 19% (75) 17% (90) 31% (90) 37% (98) 27% (56) 22% (50) 26% (459)
Gentamicin 83% (75) 61% (100) 74% (100) 66% (102) 71% (56) 73% (51) 70% (484)
Ceftriaxone 100% (3) 75% (32) 91% (99) 88% (98) 95% (57) 86% (49) 88% (338)
Tetracycline 20% (70) 14% (91) 40% (5) 50% (2) 0% (2) – (0) 18% (170)
Ciprofloxacin 99% (70) 95% (102) 99% (101) 97% (102) 98% (54) 92% (51) 97% (480)
First-line therapy (penicillin and gentamicin)* 83% (75) 61% (100) 74% (100) 66% (102) 71% (56) 73% (51) 70% (484)

*Reflects susceptibility to gentamicin only.

Article Categories:
  • Paediatrics
    • Research
Article Categories:
  • 1506
  • 1706
  • 1719

Previous Document:  Transforming Growth Factor (TGF)-? expression and activation mechanisms as potential targets for ant...
Next Document:  A cohort study of mortality predictors and characteristics of patients with combined pulmonary fibro...